Crucial research in development of promising Ebola virus treatment

August 6, 2014, The Scripps Research Institute

Laboratories at The Scripps Research Institute (TSRI) are investigating antibodies to fight Ebola virus, including the three antibodies recently used to treat two American health care workers infected with the Ebola virus.

The conditions of two Americans have reportedly improved since they received a highly experimental antibody cocktail called ZMapp, supplied by San Diego-based Mapp Biopharmaceutical.

The TSRI laboratories of Professor Erica Ollmann Saphire and Assistant Professor Andrew Ward are studying the structures of these antibodies using techniques called electron microscopy, which creates high-resolution images by hitting samples with electrons, and X-ray crystallography, which determines the atomic structure of crystalline arrays of proteins. Through these images, the team will discover exactly how the immune system molecules bind to the Ebola virus and stop it from functioning, a critical step in drug development.

Ebola virus causes an extremely virulent disease that currently leads to death in 25 to 90 percent of cases. The fast-moving virus is spread via the blood or other bodily fluids of an infected person,

"What we're showing are sites of vulnerability on the surface of the virus," said C. Daniel Murin, a graduate student in the Saphire and Ward labs. "These are the chinks in the armor of the virus and the places were you would want your anti-serum to target."

The ZMapp treatment is still in experimental stages and has not yet been approved for use outside the two recent cases. According to Saphire, ZMapp is one of the best antibody cocktails currently known, but there may still be ways to improve it. She is currently leading a $28 million National Institutes of Health-funded consortium to test antibody cocktails from laboratories around the world, with the goal of finding the best for neutralizing Ebola virus and the many other viruses like it.

An ideal antibody cocktail would ease symptoms and improve the prognosis of infected individuals—it could even work as a preventative measure, protecting healthcare workers before they enter an infected area.

The work on the Ebola is part of a larger Vaccine and Global Health Initiative at TSRI, which includes research on HIV/AIDS, influenza and tuberculosis.

Explore further: Biodesign researcher helped develop tobacco-based platform for Ebola vaccine development

Related Stories

Biodesign researcher helped develop tobacco-based platform for Ebola vaccine development

August 6, 2014
Charlie Arntzen has worked tirelessly on new platforms to deliver vaccines. He has focused on plant-based vaccine delivery systems, testing a wide range of plants as possible "manufacturing platforms" for vaccines for the ...

Experimental Ebola drug is hard to make, expert says

August 5, 2014
An experimental drug given to two American patients with Ebola is made from tobacco leaves and is hard to produce on a large scale, a leading US doctor said Tuesday.

5 things to know about Ebola outbreak in W. Africa

July 28, 2014
(AP)—There has been panic and fear about the deadly Ebola disease spreading ever since Nigerian health officials reported Friday that a Liberian man sick with the disease had traveled to Togo and then Nigeria before dying. ...

Nigeria confirms five more Ebola cases, seven in total, 2 deaths

August 6, 2014
Nigeria on Wednesday confirmed five new cases of Ebola in Lagos and a second death from the virus, bringing the total number of infections in sub-Saharan Africa's largest city to seven.

US woman with Ebola arrives in Atlanta for treatment

August 5, 2014
An American woman infected with the dangerous Ebola virus arrived at a US military base in Atlanta, Georgia, on Tuesday and is headed for treatment at a specially equipped hospital.

Sierra Leone warns of contact with Ebola infected

June 27, 2014
Sierra Leone warned Friday that it is a serious crime to shelter someone infected with the ebola virus.

Recommended for you

New long-acting approach for malaria therapy developed

January 22, 2018
A new study, published in Nature Communications, conducted by the University of Liverpool and the Johns Hopkins University School of Medicine highlights a new 'long acting' medicine for the prevention of malaria.

Virus shown to be likely cause of mystery polio-like illness

January 22, 2018
A major review by UNSW researchers has identified strong evidence that a virus called Enterovirus D68 is the cause of a mystery polio-like illness that has paralysed children in the US, Canada and Europe.

Creation of synthetic horsepox virus could lead to more effective smallpox vaccine

January 19, 2018
UAlberta researchers created a new synthetic virus that could lead to the development of a more effective vaccine against smallpox. The discovery demonstrates how techniques based on the use of synthetic DNA can be used to ...

Study ends debate over role of steroids in treating septic shock

January 19, 2018
The results from the largest ever study of septic shock could improve treatment for critically ill patients and save health systems worldwide hundreds of millions of dollars each year.

New approach could help curtail hospitalizations due to influenza infection

January 18, 2018
More than 700,000 Americans were hospitalized due to illnesses associated with the seasonal flu during the 2014-15 flu season, according to federal estimates. A radical new approach to vaccine development at UCLA may help ...

Flu may be spread just by breathing, new study shows; coughing and sneezing not required

January 18, 2018
It is easier to spread the influenza virus (flu) than previously thought, according to a new University of Maryland-led study released today. People commonly believe that they can catch the flu by exposure to droplets from ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.